Life Technologies provides notice of contingent interest payment to 2% convertible senior note holders

Top Quote As required under the indentures covering Invitrogen Corporation 2% Convertible Senior Notes due 2023 (cusips 46185RAF7 and 46185RAJ9) Life Technologies Corporation (NASDAQ: LIFE) (as successor to Invitrogen Corporation) is providing public notice to the holders of these bonds that they have the right to receive contingent interest for the quarterly interest period beginning August 1, 2010. End Quote
  • (1888PressRelease) August 04, 2010 - CARLSBAD, Calif. - As the notes have been called for redemption, the period for which contingent interest is payable begins on August 1, 2010, and continues up to but not including the redemption date of August 6, 2010.

    The contingent interest is payable because the average trading price of these notes was equal to 120% or more of the principal amount of the notes for the relevant measurement period. The amount of contingent interest payable is equal to 0.35% of the average trading price of the notes over the measurement for the contingent interest payment as defined in the indenture.

    The U.S. Bank National Association is the trustee for the notes. All questions relating to the contingent interest for the notes should be directed to Paula Oswald at The U.S. Bank National Association, (800) 934-6802.

    About Life Technologies
    Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website:

    Life Technologies Corporation
    Investor Relations
    Eileen Pattinson, 760-603-7208
    eileen.pattinson ( @ ) lifetech dot com
    Rebecca Chambers, 760-268-7971
    rebecca.chambers ( @ ) lifetech dot com

  • FB Icon Twitter Icon In-Icon
Contact Information